# US 2026/0224627 A1 · Cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224627 A1
- Document ID: US20260224627A1
- Status: Published application
- Kind: A1
- Application number: 19/459,793
- Filed: 2026-01-26
- Published: 2026-08-06
- Earliest claimed: 2020-04-08
- Assignees: Autolus Limited
- Applicants: Autolus Limited
- Inventors: Shaun Cordoba; Martin Pulé; Vania Baldan; Alex Nicholson
- Web page: https://patentgrep.com/patent/US20260224627A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/42: Cancer antigens
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4252: {Phosphatases}
- A61K 40/4271: {Melanoma antigens}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 5/0636: {T lymphocytes}
- C12N 9/16: acting on ester bonds (3.1)
- C12Y 207/10002: Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
- C12Y 301/03016: Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/11: Antigen recognition domain
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/25: Suicide switch
- A61K 2239/46: characterised by the cancer treated
- A61K 2239/57: Skin; melanoma
- A61P 37/02: Immunomodulators
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 5/0087: {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- C12N 2502/11: blood or immune system cells
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided an effector immune cell which expresses a cell surface receptor or receptor complex which specifically binds an antigen recognition receptor of a target immune cell; which effector immune cell is engineered such that when a synapse is formed between the effector immune cell and the target immune cell, the capacity of the effector immune cell to kill the target immune cell is greater than the capacity of the target immune cell to kill the effector immune cell. There is also provided the use of such a cell in methods for treating cancer, preventing allograft rejection and GVHD.

## Claims

### Claim 1

An effector immune cell which expresses a cell surface receptor or receptor complex which specifically binds an antigen recognition receptor of a target immune cell; which effector immune cell is engineered to be resistant to one or more calcineurin inhibitors.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 3)

An effector immune cell according to claim 3, which expresses:
calcineurin A comprising mutations T351E and L354A with reference to the sequence shown as SEQ ID No. 65;
calcineurin A comprising mutations V314R and Y341F and with reference to the sequence shown as SEQ ID No. 65; or
calcineurin B comprising mutation L124T and K-125-LA-Ins with reference to the sequence shown as SEQ ID No. 66.

### Claim at position 4

5-6. (canceled)

### Claim 7

An effector immune cell which expresses a cell surface receptor or receptor complex which specifically binds an antigen recognition receptor of a target immune cell; which effector immune cell is engineered to express or overexpress PD-L1 or PD-L2 or a fusion protein comprising the extracellular domain of PD-L1 or PD-L2.

### Claim at position 6

8-9. (canceled)

### Claim 10 (depends on 7)

An effector immune cell according to claim 7, which is engineered to express a fusion protein comprising the extracellular domain of PD-L1 or PD-L2 and a membrane localisation domain.

### Claim 11 (depends on 7)

An effector immune cell according to claim 7, which is engineered to express a fusion protein comprising the extracellular domain of PD-L1 or PD-L2 and a co-stimulatory endodomain.

### Claim at position 9

12-16. (canceled)

### Claim 17 (depends on 1)

An effector immune cell according to claim 1, which expresses a cell surface receptor complex which comprises: an MHC class I polypeptide; an MHC class II polypeptide; or β-2 microglobulin, linked to an intracellular signalling domain.

### Claim at position 11

18-24. (canceled)

### Claim 25

A nucleic acid construct which comprises:
(i) a first nucleic acid sequence which encodes a cell surface receptor or part of a cell surface receptor complex which specifically binds an antigen recognition receptor of a target immune cell; and
(ii) a second nucleic acid sequence which, when expressed in a cell, confers on that cell resistance to one or more calcineurin inhibitors.

### Claim 26 (depends on 25)

A vector comprising a nucleic acid construct according to claim 25.

### Claim 27

A kit of vectors comprising:
(i) a first vector comprising a first nucleic acid sequence which encodes a cell surface receptor or part of a cell surface receptor complex which specifically binds an antigen recognition receptor of a target immune cell; and
(ii) a second vector comprising a second nucleic acid sequence which, when expressed in a cell, confers on that cell resistance to one or more calcineurin inhibitors.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising a plurality of effector immune cells according to claim 1.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

A method for treating a disease, which comprises the step of administering a pharmaceutical composition according to claim 28 to a subject.

### Claim 31 (depends on 30)

A method according to claim 30, which comprises the following steps:
(i) administering a pharmaceutical composition to a subject, which pharmaceutical composition comprises a plurality of effector immune cells which express a cell surface receptor or receptor complex which specifically binds an antigen recognition receptor of a target immune cell, and which are engineered to be resistant to one or more calcineurin inhibitors; and
(ii) administering a calcineurin inhibitor to the subject.

### Claim 32

(canceled)

### Claim 33 (depends on 30)

A method according to claim 30, wherein the disease is cancer.

### Claim 34 (depends on 1)

A method for making an effector immune cell according to claim 1, which comprises the step of introducing into the cell:
(i) a first nucleic acid sequence which encodes a cell surface receptor or part of a cell surface receptor complex which specifically binds an antigen recognition receptor of a target immune cell, and
(ii) a second nucleic acid sequence which, when expressed in a cell, confers on that cell resistance to one or more calcineurin.

### Claim at position 22

35-39. (canceled)

### Claim 40 (depends on 7)

A method for making an effector immune cell according to claim 7, which comprises the step of introducing into the cell:
(i) a first nucleic acid sequence which encodes a cell surface receptor or part of a cell surface receptor complex which specifically binds an antigen recognition receptor of a target immune cell; and
(ii) a second nucleic acid sequence which encodes PD-L1 or PD-L2 or a fusion protein comprising the extracellular domain of PD-L1 or PD-L2.
